Information Provided By:
Fly News Breaks for December 17, 2019
Dec 17, 2019 | 05:33 EDT
Analysts at Piper Jaffray are buyers of Aimmune Therapeutics (AIMT), Global Blood Therapeutics (GBT) and Horizon Pharma (HZNP) into expected 2020 launches. Over the last five years, more launches have underperformed than outperformed, and the stock reactions have been largely proportionate to the level of under/over performance, the analysts tell investors in a research note. However, they point out that under the "somewhat rare circumstances" where performance has beaten expectations meaningfully, the stock reactions "can pay off handsomely." As such, Piper believes these three stocks can beat the "well entrenched biopharma default thesis to 'short the launch.'"
News For AIMT;GBT;HZNP From the Last 2 Days
There are no results for your query AIMT;GBT;HZNP